The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Theranos’s defense strategy & putting the ‘F’ in ‘FDA’

By Damian Garde

The READOUT
The Readout

‘Right-to-try’ as a business model & Wave’s DMD crash

By Damian Garde

The READOUT
The Readout

Sarepta’s big day & Theranos’ last defender

By Damian Garde

The READOUT
The Readout

The future of Theranos & pregaming Sarepta’s big day

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

China’s snapping up biotech talent & an analyst gets prison time

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Bluebird’s latest data & explaining the CRISPR-cancer link

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

IBM’s Watson woes & yet more CRISPR patents

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Topless dancers at an industry party & a questionable NASH contender

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

The latest CRISPR crisis & a mid-year biotech catchup

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Whole genome sequencing in babies & is deregulation the FDA answer?

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

BioTwitter’s Axovant problem & apps becoming drugs

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Hong Kong’s biotech pitch & Axovant’s big day

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A VC not buying your hype & Allergan’s Saunders takes some heat

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Grappling with the cost of CAR-T & a curious case study

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A controversial combination & overpromising on immunotherapy

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

NASH’s existential questions & Biogen’s buying plans

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Omeros’ FDA gambit & big news in ‘two weeks’

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Axovant’s future & the end of a bizarre saga

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A blow for combination treatments & boom times in China

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

One idea to fix drug prices & a CEO restraining order

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A surreal C-suite situation & the power of CRISPR branding

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

The second act of Gilead’s top scientist & is BACE doomed?

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Celgene’s (new) new low & when good news goes badly

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

On (not) paying for ALS & a patient’s Duchenne success story

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Amgen’s relative bargain & the dirt on Theranos

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Joe Jimenez’s apology tour & Azar’s alphabetical threats to pharma

By Damian Garde and Meghana Keshavan

The Readout

How drugs get named, how CMS shames price-hikers, & how Verily thinks about diapers

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

HHS plans a shame campaign & a biotech lifer cozies up with tech

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A rapt Rose Garden & an inflection point

By Damian Garde and Meghana Keshavan

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy